In Science this week: two proteins may help treat muscular dystrophy, and more.
The firm's first assay will be for Hodgkin lymphoma, but a liquid biopsy test for prostate cancer has also shown strong predictive power in initial validation data.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
Using a mass spec-based proteogenomic approach, the researchers identified commonalities in neoantigen presentation across mantle cell lymphoma patients.
MLL will be the first European user of Illumina's new high-throughput sequencing platform, the NovaSeq.
In PNAS this week: common, not rare ERAP1 variants linked to ankylosing spondylitis, recurrent VAV1 mutations in peripheral T-cell lymphoma, and more.
Roche has licensed and plans to commercialize the circulating tumor DNA technology, which the Stanford researchers dubbed CAPP-seq.
The companies will initially focus on developing a companion diagnostic for Merck's investigational B cell lymphoma drug M7583.
The company said its HTG EdgeSeq system and EdgeSeq Diffuse Large B-Cell Lymphoma Cell of Origin Assay may now be distributed in the EU.
Researchers used single-cell sequencing to uncover karyotype heterogeneity within mouse and human cancers and predicted that it might be linked to outcomes.
Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.
ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.
The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.
In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.